Difference between revisions of "CD138"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
*Triple negative breast cancer.<ref name=pmid25273930 >{{Cite journal | last1 = Lim | first1 = GH. | last2 = Tan | first2 = PH. | last3 = Jara-Lazaro | first3 = AR. | last4 = Thike | first4 = AA. | last5 = Sim | first5 = WC. | last6 = Yap | first6 = VB. | last7 = Yip | first7 = GW. | title = Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. | journal = Singapore Med J | volume = 55 | issue = 9 | pages = 468-72 | month = Sep | year = 2014 | doi = | PMID = 25273930 }} | *Triple negative breast cancer.<ref name=pmid25273930 >{{Cite journal | last1 = Lim | first1 = GH. | last2 = Tan | first2 = PH. | last3 = Jara-Lazaro | first3 = AR. | last4 = Thike | first4 = AA. | last5 = Sim | first5 = WC. | last6 = Yap | first6 = VB. | last7 = Yip | first7 = GW. | title = Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. | journal = Singapore Med J | volume = 55 | issue = 9 | pages = 468-72 | month = Sep | year = 2014 | doi = | PMID = 25273930 }} | ||
</ref> | </ref> | ||
*[[Plasmacytoid urothelial carcinoma]].<ref name=pmid24246859>{{Cite journal | last1 = Zhang | first1 = W. | last2 = Jiang | first2 = YX. | last3 = Liu | first3 = Y. | last4 = Yu | first4 = WJ. | last5 = Zhao | first5 = H. | last6 = Li | first6 = YJ. | title = [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 42 | issue = 7 | pages = 433-7 | month = Jul | year = 2013 | doi = | PMID = 24246859 }}</ref> | |||
==See also== | ==See also== | ||
*[[Plasma cell]]. | *[[Plasma cell]]. | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Immunohistochemistry]]. | [[Category:Immunohistochemistry]]. | ||
Revision as of 14:36, 8 December 2015
CD138, also known as Syndecan-1, is an immunostain that marks plasma cells.
Positive
- Plasma cells.[1]
- Plasma cell neoplasm.
- Triple negative breast cancer.[2]
- Plasmacytoid urothelial carcinoma.[3]
See also
References
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 554. ISBN 978-0781765275.
- ↑ Lim, GH.; Tan, PH.; Jara-Lazaro, AR.; Thike, AA.; Sim, WC.; Yap, VB.; Yip, GW. (Sep 2014). "Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.". Singapore Med J 55 (9): 468-72. PMID 25273930.
- ↑ Zhang, W.; Jiang, YX.; Liu, Y.; Yu, WJ.; Zhao, H.; Li, YJ. (Jul 2013). "[Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].". Zhonghua Bing Li Xue Za Zhi 42 (7): 433-7. PMID 24246859.
.